Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Brainstorm Cell Therapeutics Inc

BCLI
Current price
0.53 USD +0.009 USD (+1.74%)
Last closed 0.55 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 39 911 672 USD
Yield for 12 month -79.80 %
1Y
3Y
5Y
10Y
15Y
BCLI
21.11.2021 - 28.11.2021

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York. Address: 1325 Avenue of Americas, New York, NY, United States, 10019

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

2.5 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-265 000 USD

Last Year

-285 000 USD

Current Quarter

-66 000 USD

Last Quarter

-65 000 USD

Key Figures BCLI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -21 174 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -211.7 %
PEG Ratio
Return On Equity TTM -1121.9 %
Wall Street Target Price 2.5 USD
Revenue TTM
Book Value -0.08 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings Share -0.4 USD
Diluted Eps TTM -0.4 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BCLI

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BCLI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:15
Payout Ratio
Last Split Date 16.09.2014
Dividend Date

Stock Valuation BCLI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -1.8838
Price Book MRQ 65.8173

Financials BCLI

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BCLI

For 52 weeks

0.13 USD 3.37 USD
50 Day MA 0.45 USD
Shares Short Prior Month 850 265
200 Day MA 0.71 USD
Short Ratio 1.19
Shares Short 1 343 163
Short Percent 2.05 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

414.58 USD Microsoft Corporation +0.12 (+0.03%)
Detailed analytics

ETF funds


M

MDAXEX

208.70 CHF iShares MDAX UCITS ETF (DE) -11.84 (-4.92%)
Detailed analytics

Metals


Gold

2169.94 USD Gold -5.94 (-0.27%)
Detailed analytics